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Mouse models of human disease remain the bread and butter of modern biology
and therapeutic discovery. Nonetheless, more often than not mouse models do not
reproduce the pathophysiology of the human conditions they are designed to mimic.
Naturally occurring large animal models have predominantly been found in companion
animals or livestock because of their emotional or economic value to modern society
and, unlike mice, often recapitulate the human disease state. In particular, numerous
models have been discovered in dogs and have a fundamental role in bridging proof
of concept studies in mice to human clinical trials. The present article is a review that
highlights current canine models of human diseases, including Alzheimer’s disease,
degenerative myelopathy, neuronal ceroid lipofuscinosis, globoid cell leukodystrophy,
Duchenne muscular dystrophy, mucopolysaccharidosis, and fucosidosis. The goal of the
review is to discuss canine and human neurodegenerative pathophysiologic similarities,
introduce the animal models, and shed light on the ability of canine models to facilitate
current and future treatment trials.
Keywords: canine, translational, large animal model, gene therapy, neurodegeneration
INTRODUCTION
The utility of canine models of neurodegenerative diseases has increased over the last decade.
Each year, children are born with rare and devastating diseases, and characterizing underlying
pathologies remains a constant challenge. This is often attributed to a lack of appropriate
animal models. Dog models are bridging the gap in scientific studies because they share similar
pathophysiology to their human counterparts. The strong recapitulation across species is pivotal for
development of future therapies for human diseases. This is best shown by the numerous lysosomal
storage diseases (LSDs) that have been described in dogs and these models have and will continue
to play a vital role in development of safe and efficacious treatments for humans (1).
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The canine genome has strong similarities to the human,
and the increased size and complexity of the dog brain makes
it a suitable large animal model of neurologic disease (1, 2).
As models, dogs are of a size suitable for surgical guidance
and permit clinical evaluation over time. A dog’s weight,
metabolism, and pharmacokinetics are closer to a human’s than
is a rodent’s, allowing therapeutics to be tested for efficacy
and toxicity in larger doses before moving to human trials.
Coupled with the fact that they are relatively outbred, share a
similar environment, and develop many similar neurologic and
immunologic diseases, they represent an ideal animal model to
study disease pathogenesis and novel therapeutics. For example,
the immunological similarities in X-linked severe combined
immunodeficiency (XSCID), where the immunologic defect in
dogs with XSCID helped lead to the discovery of the gene
responsible for the human disease (3). Although mouse models
are invaluable for the initial assessment of gene therapy, use of
dog models with these natural diseases is an important step in
moving toward human clinical trials.
ALZHEIMER’S AND CANINE COGNITIVE
DYSFUNCTION
Alzheimer’s Disease in Humans
Alzheimer’s disease (AD) is the 6th leading cause of death in
the United States with a worldwide prevalence of 44 million
people in 2015 (4, 5). AD is a slowly progressive disease that is
insidious in onset with initial clinical signs of recent short-term
memory loss and sparing of long-termmemory (5, 6). Personality
changes, irritability, aphasia, apraxia, and agnosia amongst a
multitude of other neurodegenerative clinical signs, usually
manifest after several years (6). AD patients can live on average
8–10 years after diagnosis, with the disease lasting up to 20 years
(7). A diagnosis of AD comprises a reliable history, physical
and neurological examinations, routine laboratory examinations,
advanced imaging, and neuropathology.
There are two recognized forms of AD: familial or early-
onset, and sporadic or late-onset AD (LOAD). Most affected
individuals (>95%) suffer from sporadic or (LOAD), a
multifactorial disease where environmental factors and genetic
predispositions contribute to pathology (4, 8). A small minority
(around 5%) of patients suffer from familial or early-onset
AD due to genetic mutations in following genes: amyloid
precursor protein (APP), presenilin 1, and presenilin 2 (9–
11). The hallmark neuropathological features of AD are
extracellular accumulation amyloid plaques (amyloid-β peptide)
and intracellular accumulation of neurofibrillary tangles. There
are multiple hypotheses of AD pathogenesis which are beyond
the scope of this review.
Risk factors associated with LOAD can be either genetic or
environmental. The strong genetic component of LOAD is due to
apolipoprotein E (APOE) which has three allelic forms: APOE-2,
-3, and -4 (4, 6). The APOE4 allele is the most important genetic
risk factor and appears to enhance amyloid-β peptide aggregation
and/or decrease its clearance (6, 12). Non-genetic environmental
causes include type 2 diabetes, obesity, hypercholesterolemia,
hyperhomocysteinemia, and hypertension (8, 13–19). There
is no cure for AD and treatments are largely supportive.
Most treatments consist of pharmacotherapy (cholinesterase
inhibitors, NMDA antagonists) and psychosocial therapy
(environmental manipulation, family support, prevention of
additional medical comorbidities) (5, 20–24).
Canine Cognitive Dysfunction
Canine Cognitive Dysfunction (CCD) is a common
neurodegenerative disorder in geriatric canine patients.
The exact pathogenesis remains undetermined but is believed
to be due to the neurotoxic effects of beta-amyloid protein
accumulation in the brain. The prevalence of CCD in dogs over
the age of 8 ranges from 14 to 60% (25–28). Dogs naturally
accumulate amyloid-β peptide in their brains, with an identical
amino acid sequence to humans and similar amounts of
deposition associated with cognitive impairment (29–33).
While neurofibrillary tangles have not reported in CCD dogs, a
pre-tangle pathology has been suggested (31, 34–37). Further,
dogs do not appear to show as significant cognitive defects as
AD patients (e.g., loss of ability to eat) suggesting that CCD
progression is more comparable to early stage AD (38).
In one long term observational study the most common
clinical signs in dogs with CCD included: altered sleep wake
cycles, altered interactions, disorientation, and anxiety in ∼50%
of CCD dogs (39). The DISHA acronym is commonly used to
summarize clinical signs with CCD and includes disorientation,
altered interactions, sleep wake cycle disturbances, house soiling,
and changes in activity level (40). Concurrent medications,
other medical problems, natural sleep disturbances, and general
anxiety must be ruled out before an accurate diagnosis can
be reached. CCD dogs have age-related changes on MRI
(interthalamic adhesion thickness ≤ 5mm) that are consistent
with, but not specific for CCD (41). Another study found
that interthalamic adhesion thickness, interthalamic adhesion
thickness/brain height ratio, and lateral ventricle to brain height
ratio were all significantly lower in dogs with signs of cognitive
dysfunction than in dogs with no cognitive function. These
metrics were validated for use in quantifying brain atrophy
in patients (42). Like AD, CCD cannot be cured. The goals
of treatment are to slow disease progression and improve
clinical signs. CCD is often managed with environmental
enrichment, nutritional therapy (Hill’s b/d, Purina One Vibrant
Maturity), oral L-deprenyl (selegiline), and supplementation
with S-adenosylmethionine.
Therapeutic Testing in the Canine Model
Transformative results have not been noted in CCD dogs treated
with any therapy tested to date. A diet rich in antioxidants
like Vitamins A and E, fatty acids like DHA and EPA, and
mitochondrial protectants like lipoic acid and L-carnitine, have
been shown to slow cognitive decline in dogs (43–47). A diet
rich in medium-chain triglycerides (>6.5%) has been shown
to improve cognitive function in dogs with CCD as quantified
by 6 out of 6 metrics after 90 days, compared with 4 out
6 metrics for control diets (48). Selegiline therapy has shown
some benefit in dogs with CCD when dosed at 0.5–1.0mg/kg
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orally for 60 days, with 67.8% of dogs showing improvement in
their activity levels or sleep/wake cycles, and 77.8% showing less
disorientation or unfamiliarity with family members (49). Oral
S-adenosylmethionine (SAMe) tosylate supplementation has also
been evaluated in CCD dogs over 8 years old at 18 mg/kg orally
(50). By various behavioral and locomotive metrics, 57.1–59.5%
of dogs treated with SAMe improved after 8 weeks, compared
with 9.0–21.4% of dogs in the placebo group. Other proposed
therapies that have not yet been adequately studied include anti-
inflammatories (51, 52), phytochemicals to prevent oxidation in
the brain (53), drugs that enhance cerebral perfusion (52, 54), and
drugs that reduce anxiety or normalize the sleep-wake cycle (53).
Impacts on Patients With Disease
CCD closely resembles the early stages of AD in people, and it is
largely accepted that early intervention is better, therefore there
is great utility using the CCD dog as an animal model for testing
emerging AD therapies. Clinical trials of novel therapeutics for
AD have not been tested in CCD dogs to our knowledge, and this
is likely due to the complexities associated with conducting client
owned animal clinical trials and/or a lack of a comprehensive
natural history study of CCD. Dogs with CCD can achieve a
full lifespan (39), especially if managed with a combination of
dietary modifications (45) and environmental enrichment (55),
in contrast to AD patients who live an average of 8–10 years after
diagnosis. Therefore, objective measures that determine efficacy
will need to be based on the natural history of CCD, including
cognitive, behavioral, locomotive and/or image-based measures.
A comparative study has potential to reveal new avenues of
therapy for AD to minimize or slow progression to the lethal
stages of the disease.
ALS AND DEGENERATIVE MYELOPATHY
Amyotrophic Lateral Sclerosis in Humans
Amyotrophic lateral sclerosis (ALS) is progressively paralytic
fatal motor neuron neurodegenerative disorder described by
degeneration of upper and lower motor neurons in the brain and
spinal cord (56, 57). Amyotrophic refers to muscle atrophy due
to denervation from neuron degeneration, while lateral sclerosis
refers to the hardened nature of the posterior and lateral spinal
cord tracts. ALS is recognized in two forms: around 10% of
cases are familial (FALS), usually inherited as an autosomal
dominant trait (58–61), and 90% of cases are sporadic with no
genetic inheritance pattern. Clinical signs usually present around
50–65 years of age and manifest as twitching, cramping, and
muscle weakness which can progress to dyspnea and dysphagia
in advanced stages of the disease (62–65).
In general, it has been presumed that ALS is a disease
influenced by equally important genetic and environmental
factors. Environmental factors with possible correlations to
ALS have been studied extensively. Cigarette smoking, military
service, exposure to heavy metals, pesticide exposure, and trauma
are all risk factors under investigation for association with ALS
(66–69). Although sporadic ALS accounts for the majority of
cases, genetic causes have been known to play a role (70).
FALS involves mutations at specific genetic loci inherited in
an autosomal dominant pattern (71–73). FALS and sporadic
ALS are clinically and pathologically identical and show genetic
similarities (56, 72). Beginning with the discovery of the SOD1
gene in 1993, at least 25 genes have now been associated with
familial ALS, sporadic ALS, or both (57, 71, 74–76). Five of
these genes account for the majority of familial cases: C9orf72,
SOD1, FUS, TARDBP, and ANG (77–83). Mutations in SOD1
and C9orf72 cause familial ALS most commonly with varying
rates, with 50–60% of familial ALS patients show mutations
arising from the genes identified to date (84).
Themain pathologic observation in patients with ALS is upper
and lower motor neuron death in the motor cortex and spinal
cord, with corticospinal axonal degeneration leading to thinning
and sclerosis of the lateral portions of the spinal cord (57). In
response to degeneration of motor neurons, neuroinflammatory
processes lead to proliferation in microglia, astrocytes, and
oligodendrocytes (85, 86). A pathologic common feature in
familial and sporadic ALS is the presence of cytoplasmic protein
inclusion bodies, mainly but not exclusively in motor neurons
(57). In many cases of ALS, the main component of these
inclusion bodies is caused by aggregation of proteins encoded by
TARDBP, SOD1 or FUS (56, 57, 87). There are four recognized
phenotypic expressions of ALS: Limb-onset ALS which shows
upper motor neuron (UMN) and lower motor neuron (LMN)
signs of the limbs; bulbar onset ALS, described by disruption of
cranial nerves 9–12 resulting in speech and swallowing difficulties
with limb deterioration in later disease stage; primary lateral
sclerosis (PLS) which is described by pure UMN involvement
of the corticospinal and corticopontine motor neurons; and
lastly, progressive muscular atrophy (PMA) where lower motor
involvement dominates (56, 57). On average there is a delay of
13–18 months from onset of clinical signs to diagnosis (88). ALS
is a clinical diagnosis of exclusion from other diseases that cause
progressive UMN and LMN dysfunction, such as multifocal
motor neuropathy with conduction block (57, 89, 90). Ultimately,
ALS invariably proves fatal with few FDA approved drugs. The
main cause of mortality in patients with ALS is respiratory
failure (91).
Degenerative Myelopathy in Canines
Canine degenerative myelopathy (DM) presents clinically similar
to primary lateral sclerosis in ALS patients (92). In dogs, DM
is most common in older, large breed dogs, with German
Shepherds being classically overrepresented. More recently, DM
has been found in many other breeds, such as Pembroke
Welsh Corgis (PWCs) and Boxers (92–94). The age of onset of
neurologic signs is usually >5 years of age, with large breed
dogs having a mean of 9 years and PWCs having a mean of
11 years of age. No sex predilection is apparent. DM refers
to older dogs with diffuse axonal necrosis in the ventral and
lateral funiculi of the thoracolumbar spinal cord segments with
secondary demyelination and astrogliosis (95). DM presents as a
slowly progressive, non-painful T3-L3 myelopathy that will over
time progress cranially. The disease usually presents as UMN
pelvic limb paresis with general proprioceptive ataxia. Over
time, animals develop UMN bladder dysfunction, progressive
paraparesis, thoracic limb weakness, lower motor neuron
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weakness, and dyspnea. Compared to larger breed dogs, small
breed dogs may have slower disease progression (92).
It is important for veterinary clinicians to recognize that
DM is a diagnosis of exclusion with a definitive diagnosis
based on post-mortem histopathologic examination of spinal
cord segments. Some differential diagnoses for DM include
intervertebral disc disease, neoplasia, degenerative lumbosacral
syndrome, and degenerative joint diseases, such as hip dysplasia,
osteoarthritis, or cranial cruciate ligament ruptures (96). A
presumptive diagnosis is often made based on clinical signs,
signalment, and absence of compressive myelopathy on MRI
or myelography. CSF analysis is often performed to rule out
other causes, such as meningitis. CSF may have evidence of
albuminocytological dissociation without elevations in cell count.
However, a study on PWCs in 2007 showed no cytologic or
protein abnormalities on CSF analysis (97).
The underlying cause of degenerative myelopathy is currently
unknown. Metabolic, auto-immune, nutritional, and oxidative
pathologies have all been suggested. Genome-wide association in
PWCs DNA lead to the discovery of the highest concentration
of single nucleotide polymorphism in the region of chromosome
31, which contains the SOD1 gene (93). The authors determined
a G to A transition in exon 2 in PWCs with DM with
all five dog breeds (PWCs, GSDs, Boxers, Chesapeake Bay
Retrievers, and Rhodesian Ridgebacks) having confirmed DM
being homozygous for the SOD1 mutation. DM DNA testing is
available through the University of Missouri. The test determines
whether patients are heterozygous, homozygous, or lack the
mutation but cannot confirm whether a patient has DM. Dogs
homozygous for the SOD1 mutation are at risk for developing
DM and the test is commonly used in breeders determined to
reduce incidence of DM (92). DM carries a poor long-term
prognosis. No therapy has been effective, but most clinicians
treat patients with a variety of antioxidants and supplement
B12 vitamins. Physical rehabilitation may also help to slow the
progression of the disease (98).
Therapeutic Testing in the Canine Model
No treatment significantly increases survival time for canine
patients with DM. However, therapeutic benefits of specific gene
silencing of the superoxide dismutase (SOD1) gene is being
explored as a novel treatment for dogs diagnosed with the
disease (99). In dogs with naturally occurring DM, experimental
treatment will include adeno-associated virus AAV-Rh10-miR
anti-SOD1 injected into the subarachnoid space to explore
whether ambulatory function will persist longer compared to
control dogs. Other metrics of interest between experimental
and control groups in this study include neurological scoring,
measurement of inguinal circumference of the hindlegs, stepping
pattern measured by force plate analysis, CBC and chemistry
profiles, and degree of SOD1 silencing based on CSF collection.
Although vitamin B12 deficiency has been documented in 50%
of German Shepherd dogs with DM, anecdotal evidence suggests
that supplementation of B12 is not shown to attenuate the
progression of the disease. In people, B12 supplementation
has shown success in the treatment of degenerative cervical
myelopathy, suggesting the clinically similar diseases have
dissimilar etiologies (100).
The ER foldase called protein disulphide isomerase (PDI)
has been identified as a reliable indicator of both DM in
dogs and ALS in people, as PDI is significantly upregulated in
examined tissues from both disease processes compared with
controls. Furthermore, given co-localization of PDI and SOD1
accumulation on histopathology, it is thought that PDI may
function as a cellular defense mechanism against the misfolding
of SOD1. For this reason, PDI may represent a new target for
developing therapies against DM and ALS (101).
Impact on Patients With This Disease
Gene therapy is already being explored extensively as a therapy
for people with ALS (102). Although clinical trials for novel
therapeutics in ALS patients are showing promising results, it
remains useful to test new therapies in dogs withDMas an animal
model for ALS, given significant overlap in the pathophysiology,
especially the shared importance of the SOD1 gene in both
diseases. Setbacks in human trials may necessitate further DM
canine studies to explore either minor modifications in protocol
or new techniques entirely.
In light of the substantially lower proportion of people
who develop ALS as a result of an SOD1 mutation compared
with dogs who develop DM as a result of this mutation,
there is some debate as to whether these two conditions are
truly the same. Regardless, both DM and ALS result in up-
regulated expression of the endoplasmic reticulum stress marker
GRP78/BiP (103). Therefore, even if the pathophysiology of DM
mimics only a fraction of ALS cases (namely, those mediated
by SOD1 mutations), DM may remain a useful animal model
for ALS insofar as it could afford us insights into the interplay
between the unfolded protein response (UPR) of microglia
and astrocytes and the spinal cord inflammation seen in
the two diseases.
NEURONAL CEROID LIPOFUSCINOSIS
Neuronal Ceroid Lipofuscinosis in Humans
The neuronal ceroid lipofuscinoses (NCL) are a group of
inherited lysosomal storage disorders described in humans and
multiple animal species. With one exception, the NCLs exhibit
an autosomal recessive mode of inheritance (104). The incidence
of NCL is the United States is 1:12,500 (105) with 14 different
forms of NCL being described (CLN1-14) (106). Although
the function of many of the NCL genes remain unknown,
it is apparent that they are vital for homeostasis of cerebral
neurons (107). To illustrate, the products of CLN1, CLN2, and
CLN10 are lysosomal storage enzymes while products of CLN3,
CLN6, and CLN8 are transmembrane proteins with currently
unknown functions (104). Dementia is the main clinical sign
see in adult forms of NCL while most childhood forms have
varying clinical features that include progressive loss of eyesight,
mental and motor deterioration, seizures, and premature
death (107).
Although clinical signs are variable, the NCLs share similar
pathological characteristics: accumulation of an autoflorescent,
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periodic acid-Schiff (PAS)- and Sudan black B-positive granules
in the lysosomes of neurons and other extraneuronal tissues
(104). Cerebral and cerebellar atrophy, increased ventricular
size, decreased gyri thickness with loss of nerve cell bodies,
loss of myelin, astrocytosis, microgliosis, and ceroid lipopigment
accumulation may be observed histologically (108). Other
common pathologies noticed are optic and retinal atrophy
as well as accumulation of lipopigments in lymphocytes and
monocytes (108). NCL can overlap clinically with many other
neurodegenerative diseases. As such, one must demonstrate
accumulation of autoflorescent ceroid material in nervous tissue
to classify a disease as possible NCL (109).
Neuronal Ceroid Lipofuscinosis in Canines
All NCL genes currently identified in animals are homologs of
established NCL genes in humans, meaning that in contrast
to AD/CCD or ALS/DM, NCL is agreed to be the same
disease happening in two species (104). The first clinical
description of NCL in canines was recognized in the 1950’s
by Dr. Nils Koppang in English Setters as a generalized
metabolic disease with accumulation of lipopigments in almost
every tissue. This accumulation was most pronounced in the
central, but not peripheral, nervous system. Accumulation
of intraneuronal ceroid in canines is present at the time
of birth, prior to onset of clinical signs. Canine patients
suspected for NCL typically show at least four of the following
progressively neurologic clinical signs: loss of vision, changes
in behavior, losses of learned behavior, cerebellar ataxia,
tremors, cognitive and motor decline, sleep cycle disruptions,
and convulsions.
A strong advantage of the canine model is the more than
50-year natural history of canine NCL. Since then, NCLs have
been identified in at least 18 different canine breeds (110)
with various other breeds having reported NCL like symptoms
without genetic confirmation. While the earlier descriptions of
canine NCL focused largely on phenotype and histopathology
(111, 112), later studies utilized new technologies to define the
genetic mutations responsible for the disease, including CLN8
mutations in English Setters (113), CLN5 in Border Collies (114),
and CLN12 in Australian Cattle Dogs (115). The identification
of these mutations, along with the clinical descriptions, allowed
parallels to be made between human and canine disease. For
example, the CLN8 mutation in English Setters with NCL disease
resembles juvenile human NCL (113). The long history of
investigation into the various types of canine NCL makes it an
extremely valuable large animal model.
Although canines and humans share many phenotypic
similarities, there are some differences in presentation between
canine and human NCLs of similar genetic origin. For example,
English Setters do not show the intense retinal decline that
is a hallmark of the human disease (112) and Border Collies
show marked behavioral problems that are not as striking
in their human counterparts (114). Additionally, different
NCL mutations may be difficult to distinguish based on
presentation in canines, because symptoms are similar across
mutations (114). Canine NCL patients display diffuse cerebral
and cerebellar atrophy with an enlarged ventricular system
on MRI examination. Since the clinical signs of NCLs mimic
other lysosomal storage diseases, definitive diagnosis is based on
presence of a mutation in one of the established NCL genes (116).
Fortunately, dogs suspected of suffering from NCL can be tested
easily for any of the known mutations from a blood sample or
cheek swab (117). Like humans, dogs show differences in disease
onset, lesion distribution, and chemical storage material. This is
consistent with the view that human NCL may not be chemically
or genetically homogenous (118).
Spontaneous and induced rodent models of NCL have
their own advantages but are also limited by their phenotypic
differences from human disease, small size, and limited
cognition (113). Spontaneous NCL has been described in a
broad range of large animals, including cows, horses, and
sheep (114), but canine models have unique qualities that
set them apart. Not only do canine genetic mutations mirror
human disease, but the symptoms and clinical signs of NCL,
such as aggression, agitation, hallucinations, loss of learned
behaviors, and blindness are similar between humans and
canines (114).
Therapeutic Testing in the Canine Model
Because of its early identification, canine NCL models have
been used for clinical testing since the 1990s (119). Early
treatments tested in canine NCL models include bone marrow
transplantation (119) and dietary therapies (120). More
recently, the miniature longhaired Dachshund model of
CLN2-related NCL has been used to test the effectiveness
of enzyme replacement therapies (121, 122). Recombinant
human tripeptidyl peptidase-1 (rhTPP1) was infused into the
CSF of affected Dachshunds every other week and showed a
dose-dependent delay in the onset of neurological deficits and
an increased life span, but no effect on retinal degeneration
(122). Additionally, TPP1 adeno associated viral gene therapy
(AAV) was also tested in CLN2 Dachshunds, with a one-time
intracerebroventricular injection resulting in delayed disease
progression and increased lifespan, although retinal deterioration
persisted (123). Both treatments revealed potential benefit for
human CLN2 patients, elucidated the need for simultaneous
retinal targeting, and led to initiation of human clinical trials
(122, 123).
Impacts on Patients With This Disease
Current treatments of NCL in human patients include
Cerliponase alfa (recombinant human TPP1 proenzyme)
for CLN2 disease, involving ventricular infusions every other
week (124). Recent studies in dog models of NCL suggest that
multiple intracranial treatments of rhTPP1 could offer dramatic
improvements (122), and a recombinant PPT1 proenzyme
treatment has proved promising in CLN1 disease mouse
models (124). The one-time ventricular infusion of AAV-TPP1
investigated in CLN2 Dachshunds (123) is in phase I/II clinical
trials (124). Other gene therapy solutions have entered clinical
trial for CLN6 and CLN3 disease, initially tested in mice (124).
Other emerging treatments include immunomodulatory agents
and stem cell therapy.
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GLOBOID CELL LEUKODYSTROPHY
Globoid Cell Leukodystrophy in Humans
Globoid cell leukodystrophy (GLD), also known as Krabbe
disease (KD), is a fatal lysosomal storage disease that affects both
the central and peripheral nervous systems. GLD is caused by an
autosomal recessive mutation on human chromosome 14 (125)
affecting the β-galactocerebrosidase gene (GALC), resulting in
enzymatic deficiency of galactosylceramidase. Deficiency in this
enzyme results in decreased degradation of two lipid substrates:
galactosylceramide and psychosine. Clinical onset is divided into
four groups: infantile, late infantile, juvenile, and adult. The
infantile phenotype comprises 95% of cases with onset of clinical
signs within the first 6 months of life and death by 2 years of
age (126, 127). With infantile onset, the first initial clinical signs
include hypersensitivity, stiffness of limbs, hyperirritability, and
fever of unknown origin. As the disease progresses, regression
of psychomotor functions and convulsions present. Toward the
end of the disease, infants are decerebrate, unaware of their
surroundings, and blind. Clinical signs in the later onset forms
are more variable with the adult onset patients potentially living
a normal life span.
Unlike most LSDs, the secondary substrate, psychosine,
is more pronounced than the primary substrate (Gal-cer)
and believed to be the major cause of pathogenesis and
cytotoxicity (128–134). The hallmarks of GLD include rapid
loss of myelination and oligodendrocytes, reactive astrogliosis,
and the presence of unique globoid cells. Due to loss of
galactosylceramidase, Gal-cer cannot be broken down and has
been shown to elicit infiltration of macrophages into the brain
(135, 136). The presence of macrophages, coupled with inability
of Gal-cer breakdown owed galactosylceramidase deficiency,
leads to macrophage phagocytosis of undegradable Gal-cer
and characteristic multinucleated Periodic-acid-Schiff positive
globoid cells (128).
Psy (galactosylsphingosine) is a cytotoxic lipid that
accumulates in the nervous system. Although closely related
to Gal-cer, psy causes fatal hemorrhagic infarcts (133) in
the brain and is highly cytotoxic (137). The “psychosine
hypothesis” has been demonstrated and has survived over
the years. The hypothesis states that not only the primary
substrate, but also the secondary cytotoxic substrate, psy,
cannot be degraded and its accumulation causes loss of the
myelin-forming cells (138, 139). Classically, histopathologic
presence of multinucleated macrophages engulfed with
undegradable Gal-cer was the original means of diagnosis
(140, 141). Since then, enzymatic and genetic assays have
been developed and are valuable for a prenatal diagnosis
(128, 129, 142, 143). Unfortunately, there is no cure for GLD.
Currently, the only treatment available is hematopoietic
stem cell transplantation, which is only indicated for
pre-symptomatic patients.
Globoid Cell Leukodystrophy in Canines
In addition to humans, globoid cell leukodystrophy (GLD) has
been documented in several other species, including dogs, mice,
monkeys, and sheep. In dogs, GLD has been reported in Cairn
terriers, West Highland Terriers, Australian Kelpies, Beagles,
Poodles, and mixed breeds (144–150). As with NCL, GLD is
thought to be the same disease occurring in different species,
maximizing the usefulness of canine models in developing
therapies for humans with GLD. Canine GLD was first described
in West Highland terriers and Cairn terriers in 1966 (151).
Since its discovery, significant advancements in understanding
canine GLD have been made. Affected dogs are homozygous
for an autosomal recessive missense mutation and typically
present with ataxia or paresis of the pelvic limbs, conscious
proprioceptive deficits, and dysmetria. Spinal reflexes may be
normal early in disease and affected as the disease progresses.
Onset of clinical signs occur by 4–6 weeks of age with a
survival time of 15.7 ± 4.8 weeks (149). Analysis of leukocyte
β-galactocerebrosidase levels leads to a definitive diagnosis
(147, 152).
Histopathology of the brain shows diffuse, massive
accumulations of previously described globoid cells, as well
as extensive gliosis and perivascular lymphocytic cuffing
confined to the white matter with sparing of gray matter (153).
Demyelination of all areas of the brain, auditory system, and
peripheral nerves is present in canine patients (149). Psychosine
is elevated in tissues and CSF of GLD dogs (154) increasing
significantly over time and may be a potential biomarker of
disease (149). Although MRI and electrodiagnostics cannot
accurately achieve a definitive diagnosis, they aid to increase the
index of suspicion of GLD in canine patients and warrant blood
sample testing for the defective gene.
Therapeutic Testing in the Canine Model
Combination intravenous and intracerebroventricular delivery
of AAVrh10 expressing canine GALC was evaluated in the
GLD dog to target peripheral and central nervous system
disease, respectively. This treatment approach increased GALC
enzyme activity, reduced psychosine, and improved myelination
in both the CNS and PNS. Clinically, AAVrh10-cGALC
delayed the onset of clinical signs, improved nerve conduction
velocity, but did not correct hearing deficits. Gene therapy
treated dogs lived up to 43 weeks of age (154). In order
to improve targeting of the CNS, an intrathecal delivery
approach with AAV9 is currently being investigated in the GLD
dog. Pre-symptomatic high dose AAV9 gene therapy resulted
in significant improvement on CNS and PNS disease, while
lowering the dose and delaying the treatment was less effective
(unpublished data).
Impact on Patients With This Disease
Hematopoietic stem cell transplantation (HSCT) is the only
treatment for presymptomatic infantile GLD; however,
outcomes of transplanted patients remain poor and there
are no therapeutic options for symptomatic patients. Moreover,
HSCT does not treat the PNS disease associated with GLD
(155). Data in animal models suggest that a one-time
injection of AAV expressing GALC could offer dramatic
improvements above HSCT without the associated risk of
morbidity and mortality.
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DUCHENNE MUSCULAR DYSTROPHY
Duchenne Muscular Dystrophy in Humans
Duchenne muscular dystrophy (DMD) is an invariably fatal
neuromuscular X-linked recessive disorder caused by mutations
in the dystrophin gene, affecting 250,000 people worldwide
and one in every 5,000 male infants. The dystrophin gene is
one of the largest genes known in nature and encodes for the
cytoskeletal muscle protein dystrophin. Due to its large size, the
dystrophin gene is susceptible to mutations. Approximately 60%
of dystrophin mutations are large deletions and duplications.
The remaining 40% are point mutations or small frameshift
rearrangements. These mutations result in reading frame shift
and premature termination of protein translation. Dystrophin
and its naturally existing isoforms are significant because they
are present in nearly every cell in the body. The exact function
of dystrophin remains unclear, but roles may include myocyte
protection, cell motility, cell division, myocyte contractility,
vesicle and organelle movements, cell signaling, and maintaining
cell junctions and shape. In the muscle, dystrophin and its
associated protein complex are important in stabilizing the
plasma membrane by connecting the extracellular matrix and
cytoskeleton.Without dystrophin, muscle contraction (especially
eccentric contraction) leads to sarcolemma damage, muscle
degeneration and necrosis. Historically, death occurs due to
respiratory illness secondary to diaphragmatic compromise, but
with better ventilation systems and antibiotic treatment, fewer
deaths have been attributed to respiratory disease, with more
patients dying from cardiac involvement.
Clinical signs are not apparent at birth but begin to appear
around 2–4 years of age (156). Abnormal gait and motor delay
are the symptoms seen most frequently. Proximal limb weakness
in the pelvic limbs occurs prior to thoracic limb involvement
and often leads to wheelchair dependence in patients by 11–12
years of age (157). As the disease progresses, chronic respiratory
insufficiency and dilated cardiomyopathy, due to cardiac fibrosis,
arise and are the major causes of mortality. The exact mechanism
by which the loss of dystrophin leads to muscle disease remains
unclear, however different hypotheses have been proposed, such
as mechanical damage, loss of calcium homeostasis, oxidative
stress and failed regeneration (158).
As a consequence of muscle cell membrane damage, muscle
enzymes, such as creatine kinase, leak out to circulation. Hence, a
major serum chemistry finding in patients prior to 5 years of age
is massive increase in serum creatine kinase, at least 10–20 times
the upper reference interval. (159). Histological examinations
of muscle biopsies show degenerating necrotic muscle fibers
with macrophage invasion. Molecular testing is the main means
of diagnosis of DMD with a multiplex ligation-dependent
probe amplification and targeted high-density oligonucleotide
comparative genomic hybridization microarray, both being
available commercially. Management of DMD is often tailored
to the cardiac and respiratory complications. Early cardiac
treatment with ACE inhibitors and beta blockers is often
implemented in addition to spirometry, polysomnography,
nocturnal non-invasive ventilation, and fulltime ventilation
for respiratory decompensation (159). The only approved
gold standard pharmacological therapy is corticosteroids,
such as prednisone/prednisolone and Deflazacort, although
various additional treatment options, including gene therapy,
utrophin modulation, aminoglycoside antibiotics, antisense
oligonucleotides, and stem-cell therapy are under investigation
(160, 161).
Canine X-Linked Muscular Dystrophy
The classic animal model for DMD is the mdx mouse.
Although many advancements in understanding pathogenesis
and treatments have been made utilizing the mdx mouse model,
these mice express a milder disease phenotype with less severe
muscle changes (162). The most common and well-studied
model for DMD research is the golden retriever muscular
dystrophy (GRMD) model. Variations of the disease have since
been documented in other breeds, including Labradoodles,
Labradors, Samoyed, Brittney Spaniels, Irish terrier, Miniature
Schnauzers, Pembroke Welsh Corgi, German Shorthaired
Pointer, and Rat Terriers [reviewed in (163)]. As with the storage
diseases, muscular dystrophy in people and in dogs are thought
to be the same disease occurring in different species.
DMD in dogs is known as canine X-linked muscular
dystrophy (CXMD). In GRMD, there is a point mutation
that disrupts splicing causing the dystrophin reading frame
to be terminated. Clinical signs of affected dogs are in
general much more severe than in mdx mice. CXMD dogs
may display muscle atrophy, slow growth, alterations in gait,
ptyalism, dysphagia, plantigrade stance, lumbar kyphosis and
lordosis, exercise intolerance, inactivity, paradoxical muscular
hypertrophy, cardiomyopathy, and congestive heart failure.
Spinal reflexes may be intact early in the course of the disease
and diminish as the disease progresses.
Like humans, marked elevations in serum muscle enzymes
(such as creatine kinase, aspartate aminotransferase, and
alanine aminotransferase) are often present due to muscle
fiber damage. Within the first week of life dystrophic dogs
may be identified by serum CK levels which may be up
to 300 times normal (164). A definitive diagnosis is made
utilizing muscle biopsies. Skeletal muscle biopsies of affected
individuals show severe muscle necrosis, fiber hypercontraction,
and regeneration of almost all skeletal muscles (164). The
necrosis is accompanied by macrophages, fibrosis, and lipid
accumulation with immunohistochemistry staining revealing a
lack of dystrophin in the muscle cell membranes (95). Some
CXMD breeds (such as GRMD and Welsh Corgi) can also be
diagnosed with genomic DNA PCR (165, 166).
Therapeutic Testing in the Canine Model
and Impact on Patients With This Disease
Glucocorticoids are the most commonly used drug in DMD
patients. Several groups have tested prednisone in affected dogs
(167–169). These studies revealed some beneficial effects, such
as improvement in gait, increase of the extensor muscle force,
and elevation of the integrin level. However, the treatment
also resulted in side effects, such as reduction of flexor muscle
force, and more severe muscle pathology, especially calcification.
CXMD dogs have also been used to test other anti-inflammatory
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drugs, such as the NF-κB pathway inhibitor the nemo
binding domain (NBD) peptide (170), edasalonexent, and CAT-
1041(171). These studies suggest that anti-inflammatory therapy
can reduce muscle disease in the canine model. Unfortunately,
long-term intravenous administration of NBD was found to
induce untoward infusion reactions even in normal dogs. In
addition to anti-inflammatory drugs, CXMD dogs have also
been used to test calpain inhibitor (172), proteasome inhibitor
(173), bradykinin (174, 175), and laminin-111 protein therapy
(176). Proteasome inhibitor reduced muscle inflammation and
partially restored dystrophin-associated glycoprotein complex.
Bradykinin therapy improved heart function. Laminin-111
therapy enhanced regeneration and muscle repair. However,
calpain inhibitor failed to ameliorate the dystrophic phenotype.
Cell therapy has been explored since the early ‘90s (177).
A variety of cell types have been tested in the canine DMD
model via intramuscular or intravascular delivery. These cell
types include caninemyoblasts (178, 179), caninemesoangioblast
stem cells (180), human immature dental pulp stem cells (181),
umbilical cord mesenchymal stromal cells (182), allogenic dog
muscle stem cells isolated through serial plating (183, 184),
human adipose-derived stromal cells (185, 186), and autologous
engineered canine CD133+ cells (187). Collectively, these studies
suggest that cell therapy is relatively safe and may achieve
relatively long-term engraftment under certain circumstances.
However, these studies also show that cell therapy for DMD has
not reached its prime time yet.
The fundamental issue in DMD is dystrophin deficiency.
Hence, the primary goal of DMD gene therapy is to restore
dystrophin expression. Many approaches have been tried,
including gene replacement with plasmid (e.g., Myodys),
advenovirus, and AAV vectors, gene repair with CRISPR editing,
and exon-skipping with antisense oligonucleotides (188–193).
Gene replacement therapy has been tested using adenoviral-
and AAV-mediated methods to deliver the dystrophin gene or
engineered mini- or micro-dystrophin genes. With adenoviral
gene therapy, relatively high-level dystrophin expression (∼16%)
was achieved under immune suppression in affected dogs
following intramuscular injection of a first-generation adenoviral
vector that expressed a 6.2 kb humanmini-dystrophin gene (194).
However, very few dystrophin positive cells were detected when
the full-length human dystrophin cDNA was delivered using a
high capacity adenovirus vector (195, 196).
Due to the smaller packaging capacity of AAV and the
large size of the dystrophin gene, two approaches have been
tried for AAV-mediated dystrophin replacement gene therapy.
A highly truncated, micro-dystrophin gene (<4 kb) (197, 198)
or dual-AAV vectors used in combination to deliver a larger
payload (199, 200). The AAV micro-dystrophin vector has
been evaluated by local, regional and systemic delivery in
neonatal and young adult DMD dogs (201). AAV9 micro-
dystrophin delivered by intramuscular injection in young adult
DMD dogs showed reductions in muscle necrosis, inflammation,
calcification, and fibrosis and prevented eccentric contraction-
induced force drop (202, 203). This led to testing AAV8 and
AAV9, where persistent body wide micro-dystrophin expression
was detected up to 30 months post-injection without observable
side effects. Micro-dystrophin restored the dystrophin-associated
glycoprotein complex and mitigated inflammation, fibrosis, and
calcification. Micro-dystrophin also improved growth, increased
limb muscle force, and enhanced activity and gait. Collectively,
preclinical studies in the canine model have provided compelling
supporting data for conducting systemic AAV micro-dystrophin
therapy in human patients (204–208). Three independent clinical
trials (conducted by Solid Bioscience, Pfizer, and Sarepta) are
currently ongoing (209).
Since many important protein interacting domains are
missing in micro-dystrophin, delivery of a larger dystrophin gene
by dual AAV vectors enabled packaging of a 10 kb genome (199,
200). A recent proof of principle study demonstrated efficient
reconstitution of a split mini-dystrophin gene in the CXMD
model by intramuscular injection, which greatly mitigated
muscle pathology and improved contractility in the treated
dog (210).
Only two canine studies have investigated the gene repair
approach in the CXMD model (211, 212). Bartlett et al. injected
a DNA/RNA chimeric oligonucleotide in the limb muscle of a
6-week-old GRMD puppy. They observed sustained correction
of the point mutation in the genome and expression of the full-
length dystrophin protein, but the efficiency was too low to
mitigate muscle disease (211). CRISPR-mediated genome editing
technology has significantly enhanced gene repair efficiency
using AAV vectors encoding SpCas9 and gRNA to the 1E50
canine DMD model (212). The 1E50 dog contains a point
mutation in the conserved splicing donor sequence of intron
50. This mutation results in erroneous skipping of exon 50 in
the dystrophin transcript (213). Amoasii et al. designed a single
gRNA that targets a conserved splicing enhancer sequence at
the 5’-end of exon 51. Intramuscular or intravenous delivery
of the gRNA and SpCas9 AAV vectors to 1-month-old 1E50
puppies resulted in exon 51 re-framing or skipping in the
transcript. Safe and robust dystrophin expression was detected
for up to 2 months in most muscles in the body, including
the heart. This pivotal proof-of-principle study provides critical
support for continuous development of AAV CRISPR editing as
a viable approach to treat DMD in human patients in the future
(214, 215).
Canine DMD exon-skipping studies have been performed
using antisense oligonucleotides (AONs) delivered either directly
as a chemical/small molecule to the muscle or expressed from a
U7snRNA AAV vector. Due to the unique location of the GRMD
mutation, only multi-exon skipping (exons 6, 7 and 8) can result
in an in-frame transcript. In the CXMDj dog, a beagle carrying
the GRMD mutation was treated by three phosphorodiamidate
morpholino oligomers (two targeting exons 6 and one targeting
exon 8) by intramuscular and intravenous injection (216).
Treatment resulted in widespread dystrophin expression in
multiple skeletal muscles, attenuation of histological lesions
and stabilization of clinical symptoms (216). Further optimized
antisense oligonucleotide (AON) cocktail (e.g., vivo-morpholino
and peptide-conjugated morpholino) showed near wild type
level expression for at least 2 months following intramuscular
injection and ∼5% of the wild type level following intravascular
injection in the heart and most skeletal muscles. Systemic
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delivery did not improve skeletal muscle histology and function.
However, cardiac conduction abnormalities were significantly
ameliorated (217, 218).
The AAV U7snRNA approach, where AAV encoded antisense
oligonucletotides are fused with the U7 small nuclear RNA
are transcribed from the U7 promoter (219–222), showed
persistent dystrophin restoration, muscle force improvement and
correction of the dystrophic phenotype. However, a gradual loss
of dystrophin- positive myofibers was seen during a 5-year follow
up (220, 222). Furthermore, the new study showed that limb
perfusion of the U7snRNA AAV8 vectors did not induce the T
cell response to newly synthesized dystrophin nor to AAV capsid
(207). Cardiac rescue is attained with U7snRNAAAV6 vectors by
percutaneous transendocardial delivery in the GRMD dog heart
(219, 221). Collectively, these studies support initiation of a phase
I trial in DMD patients.
An important concern of dystrophin gene replacement and
repair therapy is the potential immune response to the novel
dystrophin protein generated following the therapy. This concern
can be greatly minimized if a therapeutic gene already exists
in the patient’s body. Utrophin, an autosomal paralogue of
dystrophin, is highly enriched in the neuromuscular junction
and myotendinous junction in normal muscle and is a potential
dystrophin-independent strategy to circumvent the potential
immune response to the novel dystrophin protein. An adenovirus
carrying a 6 kb synthetic mini-utrophin gene was injected
intramuscularly in newborn CXMD affected puppies and, in
the presence of cyclosporin, mini-utrophin expression lasted
for 2 months (223). More recently, an AAV vector carrying a
micro-utrophin gene was tested in GRMD dogs and the German
Shorthaired Pointer model (224, 225). In neonatal GRMD dogs,
systemic AAV micro-utrophin delivery did not induce innate
immune response. In the German Shorthaired Pointer model, the
entire dystrophin gene is deleted. Intramuscular injection of an
AAV micro-dystrophin vector to the adult German Shorthaired
Pointer dogs induced the T cell response and had no muscle
protection. However, injection of an AAV micro-utrophin
vector resulted in robust micro-utrophin expression and muscle
protection without inducing the T cell response (224).
An alternative approach to treat muscular dystrophy is to
increase muscle mass by inhibiting the myostatin pathway. A
secreted dominant-negative myostatin peptide with intravenous
AAV injection in young adult GRMDdogs significantly increased
muscle mass and reduced muscle fibrosis and the serum creatine
kinase level (226). Interestingly, myostatin heterozygous GRMD
dogs exhibited disproportional flexor muscle hypertrophy and
atrophied extensor muscles (227). Subsequently, severe postural
changes and aggravated joint contracture were observed.
A molecular hallmark of DMD is the aberrant elevation
of the cytosolic calcium level. Calcium upregulation activates
protease and phospholipase, triggers protein degradation and
membrane damage, and eventually results in muscle necrosis;
therefore, calcium homeostasis restoration has been suggested
as a therapeutic target for DMD. Sarco/endoplasmic reticulum
calcium ATPase 2a (SERCA2a) is a highly efficient calcium
pump that transports cytosolic calcium to the sarcoplasmic
reticulum. AAV-mediated SERCA2a expression has been shown
to ameliorate muscle disease in dystrophic mice in young
adult CXMD dogs (228, 229). Treatment significantly improved
calcium uptake, reduced calpain activity and enhanced muscle
function (230), suggesting that AAV SERCA2a delivery is a highly
promising strategy to treat DMD.
MUCOPOLYSACCHARIDOSIS
Mucopolysaccharidosis in Humans
In humans and animals, the mucopolysaccharide storage diseases
(MPS) are due to lysosomal storage enzyme deficiencies leading
to decreased degradation of glycosaminoglycans (GAGs). GAGs
are important in cellular communication and regulation and
provide structural support to the extracellular matrix; therefore,
GAG accumulation occurs in many organ systems leading to a
multisystemic clinical disease. Seven different forms of MPS (I-
VII) exist due to defects in eleven enzymes (231). This review will
focus on MPS I, III and VII.
MPS I, like most lysosomal storage diseases, is due
to autosomal recessive inheritance leading to deficiency or
absence of activity of α-L-iduronidase (IDUA) enzyme causing
accumulation of heparan sulfate (HS) and dermatan sulfate
(DS). MPS I was initially recognized as three clinical syndromes
(Hurler, Hurler-Scheie, and Scheie) but due to clinical and
biochemical overlap, a description of severe or attenuated is
often implied. Common clinical signs in patients with MPS I
include corneal clouding and subsequent vision loss, cognitive
impairment, coarse facial features, hearing loss, macroglossia,
cardiomyopathy, hydrocephaly, hepatosplenomegaly, hernias,
and limited joint mobility (232). Patients with severe MPS
I experience cardiorespiratory compromise and death within
their first decade of life, while patients with the attenuated
form have wide variation from death to a clinically normal
life span (232).
MPS III, Sanfilippo syndrome, is due to autosomal recessive
inheritance and is due to loss of function of one of the
four enzymes involved in heparan sulfate catabolism leading
to four different subtypes A-D. MPS III A and B are the
most common forms seen clinically and most severe (233–237).
The allelic heterogeneity and polymorphisms of the MPS III
subtypes makes them difficult to separate based on phenotype.
Interestingly, while other MPSs present with intense peripheral
disease involvement, patients with MPS III typically present with
neurologic and cognitive impairments (231). Although little is
known about early disease development, MPS III mainly affects
the neurons of the central nervous system causing dementia,
mental retardation, delayed development, and neurological
dysfunction (157, 238, 239). Typical neuropathological lesions
include loss or ballooning of purkinje cells and accumulation
of molecular layer dendrites with storage material (157, 240–
242). Death usually occurs in the patient’s early twenties to early
thirties, for patients with the severe form, while patients suffering
from the attenuated form have longer survival times (243–245).
MPS VII, caused by deficient activity of β-glucuronidase,
was first described in a child in 1973 (246). This autosomal
recessive disorder has multisystemic manifestations, including
organomegaly and skeletal, central nervous system (CNS),
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cardiovascular, and ocular abnormalities (1). The prevalence at
birth is reported to range between 1/345,000 and 1/5,000,000.
However, the frequency of the disease may be underestimated
as the most frequent presentation is the antenatal form, which
remains underdiagnosed (231). MPS VII shares some symptoms
with MPS I andMPS III, however, one unique and distinguishing
clinical feature is the unexpectedly high proportion of patients
(40–45%) with a history of non-immune hydrops fetalis (NIHF)
(247). Cases are classified according to their phenotype into
three different groups: (1) neonatal non-immune hydrops fetalis
(NIHF), (2) infantile or adolescent form with history of hydrops
fetalis and (3) infantile or adolescent form without known
hydrops fetalis (248). The patients with prenatal-onset hydrops
who survive gestation die in early infancy of heart, kidney or
respiratory failure (247, 248). Patients surviving infancy can have
a wide range of clinical manifestations from mild to severe; rare
patients with milder manifestations of MPS VII have survived
into the fifth decade of life (247, 248). Cognitive impairment
is a common finding in MPS VII patients. Most patients have
short stature, coarse facial features and skeletal abnormalities
(231, 249). Almost half of patients with the infantile or adolescent
form of the disease are able to walk by themselves without
assistance; however, most patients lose this ability with time
due to hip dysplasia by 10 years of age (247, 248). Corneal
clouding, frequent upper respiratory infections, heart disease,
hearing impairment and delayed speech development are among
the clinical presentation of the disease (231, 247, 248). Common
causes of death include complications of hydrops fetalis with
respiratory and renal failure, heart disease, decreased pulmonary
function and/ or obstructive airway disease and aspiration (247,
248).
Mucopolysaccharidosis in Canines
MPS I
MPS I in canines most closely resembles MPS I Hurler syndrome
in humans due to GAG and sphingolipid accumulations in
CNS neurons in both species (250). Breeds typically affected
include Plott Hounds, Miniature Pinchers, mixed-breed dogs
(95), and Rottweilers (251). A multitude of clinical signs may
be apparent due to GAG accumulation in many different
organ tissues. Ocular changes and subsequent vision loss are
common in canine MPS I. Corneal clouding occurs due to GAG
accumulation in corneal stromal cells and scleral fibroblasts (252,
253). Aqueous flare, corneal neovascularization, and preiridal
fibrovascular membranes are commonly observed (252–254).
Vacuolation of bulbar conjunctiva, iris, choroid, and scleral
cells is sometimes seen (253). Changes to the cardiovascular
system include cardiac valvular insufficiencies, right ventricular
enlargement, and arterial vascular lesions. In arteries, there is
intimal thickening of the proximal and distal aorta with nodular
plaques projecting from the walls behind the semilunar valves
(255). Radiographically, joint effusion, lysis, severe secondary
degenerative joint disease, periarticular bone proliferation, and
narrowing of the intervertebral disc spaces may be evident (256).
Corneal, dermal, and synovial biopsies show cells with various
dilated vesicles and a fine granular internal matrix (256). On
cerebral MRI, there is white matter volume loss of the corpus
callosum, varying degrees of ventricular enlargement, cortical
atrophy, and alterations in signal intensity (257).
MPS IIIa
Naturally occurring MPS IIIA has been described in Wirehaired
Dachshund dogs and Huntaway dogs (258, 259). The onset of
clinical symptoms in the Dachshund dog starts at 3 years of
age and includes mild gait and postural reaction deficits in the
thoracic limbs, coarse tremor of the head, pelvic limb ataxia
and frequent stumbling and falling. The symptoms progress
gradually over 2 years to severe generalized spino-cerebellar
ataxia (258, 259). The Dachshund dogs contain a small amount of
residual SGSH activity in skin fibroblasts. In contrast, Huntaway
dog are completely deficient of SGSH activity, which may
explain the severity of the disease in this canine model (259).
The clinical onset of the disease in the Huntaway dog model
occurs at 1.5 years of age with symptoms, including presence of
ataxia and hypermetria in all four limbs, prancing gait affecting
the forelegs, difficulty jumping, and loss of learned behavior
(259). Huntaway dogs have similar disease progression and
biochemical characteristics to that observed in severely affected
MPS IIIA patients (259). The movement disorders appear in
Huntaway dogs to be attributed to lesions in the cerebellum
(260). Significant accumulation of secondarily stored lipids and
subsequent loss of Purkinje cells is observed in this dog model
(261). The loss of Purkinje cells and other abnormalities of the
cerebellum are consistent with neurologic signs in Huntaway
dogs, including ataxia, hypermetria, and a wide-based stance
(261). Disease-related pathology is also severe in cerebral cortex
and brainstem (261). In addition to accumulation of primary and
secondary storage material, microgliosis and neuroinflammatory
changes are present in the brain from the infant-pediatric-stage in
MPS IIIA brain (262). In addition to brain, various tissues show
disease related pathology (261).
MPS IIIb
MPS IIIb is observed in Schipperkes where the mutant allele
is very prevalent (258, 259, 263). It is typically present in dogs
around 2 years of age and leads to euthanasia prior to 5 years
of age. Initial pathologic studies of Schipperkes showed that the
major tissues affected in dogs (liver, kidney, CNS) were consistent
with human. The most impressive finding in the Schipperkes
with MPS IIIb was an almost complete loss of cerebellar Purkinje
cells (263). Humans show varying degrees of cerebellar pathology
leading to the belief that this may be a species sensitivity to HS
accumulation seen in canines (263).
MPS VII
Canine MPS VII has been identified in mixed breed dogs,
German Shepherds and Brazilian Terriers (264–266). Features
in MPS VII dogs resemble those in humans, except mental
retardation, which is difficult to assess, and hepatosplenomegaly
which is less severe (267). Affected dogs excreted chondroitin
4- and 6-sulfates and dermatan sulfate in urine (268). The
affected dogs present typical MPS VII features, including, facial
dysmorphia, chest deformity, short stature, and corneal clouding
(268). By 6 months of age effusions in knee and elbow joints are
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normally present and affected dogs are unable to stand or walk
(267, 269). Cardiac abnormalities are variable between dogs and
include mitral valve thickening and regurgitation, larger aortic
dimensions in both the long and short axes, and aortic valves
that are subjectively thicker (268, 270). Histologically, in the
untreated dogs the vascular smooth muscle cells of the aorta
become enlarged and rounded with highly vacuolated cytoplasm
(268). In addition, prominent nodular thickening of the mitral
valve is present with cytoplasmic vacuolation seen by light and
electron microscopy, similar to that reported in children and to
other animals with MPS (268).
Therapeutic Testing in the Canine Model
There are different approaches available to treat MPS. Here we
describe enzyme replacement therapy (ERT) and gene therapy
(249, 269). ERT can be done through intravenous (IV) or
intrathecal (IT) administration and internalization of the enzyme
in cells occurs via the M6P receptor (M6PR), which present on
the surface of most cells (271–273). IV ERT has been shown to
be effective in treatment of canine model of MPS I by reducing
lysosomal storage in liver, spleen, kidney, lymph nodes and
lungs; however, the enzyme activity in brain is not significant
(250, 274). IV ERT has been effectively used for treatment of non-
neuronopathic MPS I, MPS II and MPS VI in different animal
models; however, it is not effective for treating the neurological
manifestation of MPS, as IV administered enzymes cannot be
delivered beyond the blood-brain barrier (275). In addition,
IV ERT does not address the disease pathology in joints and
bone (276).
To address the limitations of IV ERT, IT ERT has
been investigated, which resulted in improvements of clinical
signs and/or neuropathology (277–280). IT administration of
recombinant human iduronidase (rhIDU) in MPS I dogs, 4
times weekly, demonstrated that the enzyme can adequately
penetrate the CNS, achieve levels that are many fold higher
than normal and decrease GAG levels in brain, spinal cord
and spinal meninges (281). Cisterna magna administration of
rhIDU, repeated weekly, monthly or quarterly, in canine MPS I
showed promising results where the mean iduronidase levels in
brain, spinal cord and spinal meninges were several folds above
normal and GAG storage in the brain was normalized (282).
In Huntaway dogs, weekly injection of recombinant human
sulfamidase (rhSGSH) into the cerebellomedullary cistern for up
to 4 weeks, resulted in dose dependent distribution of SGSH
to the brain and spinal cord. At high concentrations, rhSGSH
was detected in cerebellum, brainstem, all levels of the spinal
cord and most rostral areas of the cerebral cortex; however,
deep brain structures, e.g., hippocampus, caudate and thalamus,
showed lower rhSGSH activity (283). This study was repeated
with treatment of younger MPS IIIA dogs (up to 23 weeks of
age) and demonstrated that the enzyme delivery via CSF reduces
neuropathology (284).
To overcome the limitations of ERT, ex vivo and in vivo
gene therapies have been investigated in small and large animal
models of MPS. Hepatic gene therapy in MPS VII dogs using
retroviral vector expressing canine beta-glucuronidase GUSB
resulted in normal activity of serum GUSB for up to 14 months
(267). Treated MPS VII dogs had improvements in bone and
joints abnormalities and retained the ability to run. They did
not develop valve thickening and had no corneal clouding (267).
Neonatal retroviral gene therapy in MPS VII dogs has been
shown to have long term effects and could increase the life span of
treated dogs up to 11 years, with treated MPS VII dogs retaining
the ability to walk during their extended lives and showing
reduced cardiac valve disease (285).
AAV gene therapy has also been used for treatment of MPS
VII dogs. Safety and efficacy of AAV5, directly injected into
putamen and centrum semiovalae, was demonstrated in MPS I
and MPS IIIB dogs (286). Cisterna magna injection of AAV9
expressing human IDUA in MPS I dogs resulted in widespread
CNS transduction and subsequent correction of brain storage
lesions in a dose-dependent manner (287). The thickening of
meninges, which contribute to spinal cord compression in MPS I
patients was reversed (287). Another study compared therapeutic
effect of IV, cisterna magna and combined routes of injection
of AAV9 or AAVrh10 vectors expressing canine GUSB in MPS
VII dogs (288). While IV treated dogs showed reduced storage
in non-CNS tissues and low GUSB expression in CNS, the IT
treated dogs had widespread GUSB activity in neuronal tissues,
including cerebrum, spinal cord and sciatic nerve. The dogs that
received the dual treatment using two different AAV serotypes
maintained mobility throughout the study. The GUSB levels in
CNS of this group mimicked the IT only dogs and the peripheral
tissue levels mirrored those of IV treated dogs (288).
Impact on Patients With This Disease
Enzyme replacement therapy (ERT) via IV infusion of
recombinant human enzyme is available for MPS I, II, and
VI in the United States, Europe, and over 40 countries worldwide
(289). IV ERT received FDA approval for MPS VII treatment in
2017. Studies of patients during the trial and follow-up studies
indicate that this treatment can stabilize or reverse many aspects
of the disease. IV ERT has been shown to decrease the urinary
GAG excretion, size of liver and spleen, progression to heart
failure and sleep apnea for MPS I patients (290–292). Overall,
patients have improved ability to perform normal activities of
daily living. However, cardiac valve disease and skeletal disease
do not generally get treated with ERT if pathological changes are
already present (276, 289). Airway disease improves, but usually
does not normalize (289). These observations suggest that early
initiation of therapy before the onset of clinical symptoms may
be more beneficial (289). Clinical observation has not supported
neurocognitive benefit for patients with CNS manifestation since
the enzyme at the labeled doses cannot cross the blood-brain
barrier (289, 293). IT ERT has been performed to address the
CNS disease of MPS IIIA patients. A phase I/II study using an
IT drug delivery device demonstrated the safety of this delivery
method, and a consistent decline of the heparan sulfate in CSF
was documented in all patients following the administration of
the first dose (294).
AAV gene therapy as a strategy to treat systemic or
CNS manifestation of MPS is being investigated in ongoing
clinical trials for different types of MPS, including I, IIIA,
and IIIB using AAV6, AAV9, and AAVrh10 (clinicaltrials.gov:
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NCT02702115, NCT03580083, NCT03315182, NCT04088734,
NCT02716246, NCT03612869).
FUCOSIDOSIS
Fucosidosis in Humans
Fucosidosis is a rare, autosomal recessive, lysosomal storage
disease caused by a deficiency of α-L-fucosidase. The biological
role of this enzyme is to catalyze removal of fucose moieties
from glycoproteins and glycolipids, therefore it affects all
tissues. Enzymatic deficiency leads to accumulation of
storage material composed mainly of glycoasparginases
(glycoproteins) with mucopolysaccharides, oligosaccharides, and
glycolipids accumulating to lesser extents (295–298). Storage
accumulation takes place in the skin, heart, pancreas, liver,
thymus, kidneys, and brain. Accumulation of glycolipids and
glycoproteins in the brain leads to cell death and neurologic
symptoms. Fucosidosis is progressive, resulting in cognitive
and progressive motor impairments as the most characteristic
clinical signs. Common clinical signs in human patients include
mental retardation, neurologic deterioration, coarse facial
features, growth retardation, recurrent infections, dysostosis
multiplex, angiokeratoma, seizures, and organomegaly (296). A
combination of dark and clear vacuoles is unique and typical for
fucosidosis with cellular vacuolation of the liver, brain, peripheral
nerves, pancreas, skin, conjunctiva, and fibroblasts present to
varying degrees on histopathology (296). Infantile cases have
been shown to exhibit early CNS myelin loss as a pathological
feature (299–302). The mutation causing enzymatic deficiency
resides in FUCA 1 gene (303) with early analyses describing
obliteration of an Eco RI restriction site and deletions of at least
two exons at the 3’-end of FUCA1 (296).
Fucosidosis has a worldwide distribution and has been
classically identified as taking two forms: a severe form, type
I, and a less severe form, type II with further investigations
pointing toward a clinical continuum rather than distinct disease
forms. A diagnosis is confirmed by α-L-fucosidase activity levels
below 5% in the urine, leukocytes, cultured fibroblasts, or other
tissues obtained by biopsy or autopsy (296). Fucosidosis displays
a bimodal distribution of survival in human patients (296) with
43% dying before 10 years of age and 41% after age twenty, and
patients with early symptom presentation and rapidly progressive
disease tending to have shorter lifespans.
Fucosidosis in Canines
As in humans, fucosidosis in canines is due to an autosomal
recessive enzymatic deficiency of α-L-fucosidase (304) and is the
only animal model for the human disease. In dogs, fucosidosis
affects English Springer Spaniels and is a severe, progressively
fatal neurodegenerative disease (305). Compared to humans,
canines show a relative consistency in neurologic clinical signs
and pathology. Neurologic signs typically present around 12–18
months and progress to death or euthanasia before the animal
reaches 4 years of age. In the first year of life affected animals
are clinically normal. Gait and behavior deficits (resistance to
restraint, anxiety) manifest prior to 30 months of age progressing
to severe ataxia and mental deterioration that requires humane
euthanasia prior to 40 months of age (306). Canine patients
may exhibit various neurologic abnormalities, such as postural
reaction deficits, muscle tremors, circling, nystagmus, dysphagia,
regurgitation, falling, unpredictable behavior, and jaw chattering
(307). The molecular defect underlying canine fucosidosis is due
to a 14 base pair deletion at the 3’ portion of exon 1 resulting
in a frameshift and subsequent production of a premature stop
codon in exon 2, producing a foreshortened and unstable protein
product (308).
The frontal cerebral cortex of affected dogs shows extensive
cytoplasmic vacuolation of neurons and glial cells (305). The
cerebellum, striatum, thalamus, and corpus callosum show
intermediate pathology and there is an absence of vacuolation in
the lumbar spinal cord (309). This excessive vacuolation can lead
to palpably enlarged peripheral nerves on physical examination
as well as vacuolated lymphocytes on blood smears and bone
marrow samples (304). Hypomyelination is a characteristic of
many lysosomal storage diseases and is present in human and
canine fucosidosis. In dogs, the survival of the oligodendrocytes
in the early myelinating cerebellum is significantly reduced due
to excessive vacuolation, increased oligodendrocyte apoptosis
leading to reduced expression of myelin-related genes and
decreased axonal density (307). Definitive diagnosis is reached by
demonstrating reduced α-L-fucosidase in leukocytes, plasma, or
skin fibroblasts and should be suspected in young adult English
Springer Spaniels with neurological deterioration. A diagnosis is
further supported by palpably enlarged peripheral nerves, blood
smear lymphocytic vacuolation, or vacuolation in peripheral
nerve biopsies (304).
Therapeutic Testing in the Canine Model
Bone marrow transplantation (BMT) and intracisternal enzyme
replacement therapy (ERT) are the two current treatment
modalities for canine fucosidosis. BMT was first explored in
the early 1990s and remains the treatment of choice to amend
the clinical disease associated with fucosidosis (310). Animals
that maintained long term engraftment and were treated at 2–4
months of age, before onset of clinical signs, showed definitive
reduction of neurologic disease and improvement in pathologic
lesions. Whereas, animals that were treated after 6 months of
age, late in clinical disease, showed little improvement in clinical
signs and central neuronal storage. These findings illustrate that
BMT in severely affected human patients is not recommended.
After BMT, all dogs showed a rapid and sustained increase in α-
L-fucosidase activity in plasma and leukocytes with stabilization
at over 100% of donor levels in leukocytes and 30% of donor
activity in plasma (310). Unfortunately, BMT is not benign and
includes substantial associated risks, need for appropriate donors,
and limited use for severely affected patients.
Low dose monthly intracisternal infusions of canine
recombinant α-L-fucosidase in patients with fucosidosis resulted
in increased enzymatic activity by 2–72% in the spinal cord and
most areas of the brain with substrate reduction ranging from 0
to 80% (311). ERT showed significant improvements in cortical
astrocytosis, LAMP-1 gene expression, deep cerebrocortical
vacuolation, and superficial cortex ‘vacuole per neuron’ while
showing small improvements in microgliosis, myelination, and
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cortical neuron loss (312). Studies of ERT in canine fucosidosis
have shown increased survival of cortical pyramidal neurons
with little effect on cerebellar neurons demonstrating that
cerebellar clinical signs (ataxia, hypermetria, proprioceptive
deficits) may not be prevented (312). Additionally, the enzymatic
activity in patients with ERT proved unsatisfactory in reducing
substrate levels in many CNS regions and did not match the
sustained enzymatic activity achieved with BMT (311).
Impacts on Patient With This Disease
BMT has been carried out in human patients with results similar
to canine patients (302, 313). As previously mentioned, dogs
are the only large animal model for this disease and studies in
fucosidosis dogs have helped pave a path for BMT in humans.
Accurate diagnosis must be made early in disease pathogenesis as
CNS deterioration progresses to death and may not be corrected
with later transplatation. Long term follow-up in canine and
human patients is required to better evaluate the benefits of BMT
in regard to quality of life and progression of neuropathology,
although, until gene therapies become readily available, BMT
remains the treatment option for an otherwise lethal disease.
SUMMARY
Dogs faithfully recapitulate human diseases, with similar
phenotypes, biodistribution complexity, immune responses and
therapeutic efficacy as human patients. These models have
proven invaluable in the development of the therapeutics
described here and testing in these models continues to result
in promising results, worthy of first-in-human clinical trials for
these terrible diseases.
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